Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5396489 | 0.84 | KMT2A (0.58) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL6830549 | 0.84 | SMN1; SMN2 (0.58) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL15151521 | 0.79 | RAB9A (0.63) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL6828407 | 0.79 | RAB9A (0.40) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL6828515 | 0.79 | MAPT (0.52) | RAB9ANPC1CASP3SENP8SENP7 | |
| SCHEMBL6825638 | 0.78 | MAPT (0.47) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6828406 | 0.77 | SMN1; SMN2 (0.52) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL5731634 | 0.75 | RAB9A (0.61) | RAB9ANPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL11223090 | 0.75 | TP53 (0.59) | RAB9ANPC1ALDH1A1KMT2AHPGD | |
| SCHEMBL6828198 | 0.75 | MAPT (0.60) | RAB9ANPC1ALDH1A1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | RAB9A 1116/4885NPC1 2234/4885CASP3 4121/4885 |
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | PHKG1, PHKG2, MAP3K20 | RAB9A 1487/4885NPC1 2915/4885CASP3 3871/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | RAB9A 3727/4885NPC1 4506/4885CASP3 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.